1. ABOUT US

    #

    about us

    Our business research and market analysis helps organizations across different industry verticals solve their business problems. We are always scrupulous about our work and provide customized market research reports revealing the hidden truths on different verticals like pharmaceutical, oil and gas, telecommunications, real estate, logistics, energy, healthcare, technology, FMCG, food & beverages and media sectors.

    Read More
  2. RESEARCH REPORTS

    RESEARCH REPORTS

    RESEARCH REPORTS

    Our business research and market analysis helps organizations across different industry verticals solve their business problems. We are always scrupulous about our work and provide customized market research reports revealing the hidden truths on different verticals like pharmaceutical, oil and gas, telecommunications, real estate, logistics, energy, healthcare, technology, FMCG, food & beverages and media sectors.

    Read More
  3. METHODOLOGY

    #

    METHODOLOGY

    Azoth Analytics creates in-depth research reports by recording, interpreting and analyzing information through primary and secondary research. Our strategic market sizing and data dredging techniques include secondary research, interviews with key market players and industry experts and use of industry specific statistical tools which helps in designing and planning effective research for our global and local clients.

    Read More
  4. Consulting

    #

    Consulting

    Azoth Analytics Consulting assists clients across the globe to enter, progress, and develop in the targeted market through our fact-based business intelligence. We deliver practical and implementable solutions to our domestic and international clients. Our analysts are skilled with techniques of data gathering, market sizing, forecasting, analyzing and providing competitive intelligence and provide progressive research in verticals including healthcare & pharmaceutical...

    Read More
  5. media center

    #

    media center

    Our business research and market analysis helps organizations across different industry verticals solve their business problems. We are always scrupulous about our work and provide customized market research reports revealing the hidden truths on different verticals like pharmaceutical, oil and gas, telecommunications, real estate, logistics, energy, healthcare, technology, FMCG, food & beverages and media sectors.

    Read More
news

     Home >> Research Report >> Healthcare & Pharma >> Global Anemia Drugs Market (Iron Deficiency, Sickle Cell, CKD, Aplastic Anemia): Analysis By Region, By Country (2016-2021)
 

Global Anemia Drugs Market (Iron Deficiency, Sickle Cell, CKD, Aplastic Anemia): Analysis By Region, By Country (2016-2021)-(By Type - Iron Deficiency Anemia, Chronic Kidney Disease related Anemia, Sickle Cell Anemia, Aplastic Anemia; By Region-North America, Europe, APAC, Latin America, MEA; By Country - USA, Canada, UK, Germany, India, Brazil, South Africa)

 
Publish Date:October 2016
No. of Pages:175
Format: Pdf (Instant Download)
 
 
Social
Electronic Access - Single User License toll
$2600
 
Electronic Access - Multi User License toll
$4000
 
Hard Copy Mail Delivery toll
$2800
 
 
Executive Summary

A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of global anemia drugs market on the basis of Type (Iron Deficiency Anemia, Chronic Kidney Disease related Anemia, Sickle Cell Anemia, Aplastic Anemia), By Region (North America, Europe, APAC, Latin America, MEA); By Country (USA, Canada, UK, Germany, India, Brazil, South Africa).

Rising development of pipeline drugs combined with the growing awareness of disease in developing countries has resulted in the growth of Anemia Drugs market. Anemia Drugs has been majorly caused due to the lack of iron intake and less iron absorption mainly among pregnant women, women of reproductive age and young children.

Among the various types of anemia, market is expected to be driven by CKD anemia, due to the growing research and development towards new biosimilars such as Hypoxia-inducible factors. However, launch of late pipeline drugs such as Rivipansel and Vepoloxamer for sickle cell anemia treatment are anticipated to drive the market in forecast period. 

While developed regions will continue to dominate the market in terms of revenue, emerging nations are expected to respond to the market optimistically due to the developing healthcare infrastructure and rising focus on healthcare among the growing middle class population.

Global Anemia Drugs Market is forecasted to grow at a CAGR of 9.05% during 2016 – 2021F, on account of rising incidences of anemia globally.
North America region remains the major market followed by Europe in the actual period, while APAC and ROW region will witness strong growth in the forecast period.

According to Azoth Analytics research report, Global Anemia Drugs Market: Trends, Opportunities and Forecasts (2016-2021), Global Anemia Drugs market is projected to exhibit a CAGR of over ~9.05% during 2016 - 2021. On the basis of market segment, Global Anemia Drugs Market has been segmented by Type (Iron Deficiency Anemia, Chronic Kidney Disease related Anemia, Sickle Cell Anemia, Aplastic Anemia); By Region-North America, Europe, APAC, Latin America, MEA; By Country-USA, Canada, UK, Germany, India, Brazil, South Africa)

Scope of the Report

The report provides Segmentation and Pipeline Analysis by Anemia Type 
• Iron Deficiency Anemia 
• Chronic Kidney Disease related Anemia 
• Sickle Cell Anemia 
• Aplastic Anemia

The report provides coverage by Region
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa (MEA)

The report provides coverage by Country
• USA
• Canada 
• UK
• Germany
• India
• Brazil
• South Africa

Customization of the Report

The report could be customized according to the client’s specific research requirements. No additional cost will be required to pay for limited additional research.  

Table of Content

1. Research Methodology

2. Executive Summary

3. Strategic Recommendations
3.1. North America and Europe to Generate High Revenue
3.2. Opportunity in Rare Anemia
3.3. Growing Inclination Towards Hypoxia inducible factor (HIF) Stabilizers

4. Global Anemia Drugs Market: An Overview

4.1. Product Overview

4.2. Global Anemia Drugs Market
4.1.1. By Value (Historic 2011-15)
4.1.2. By Value (Forecast 2016E-2021F)

4.3. Global Iron Deficiency Anemia Drugs Market
4.2.1. By Value (Historic 2011-15)
4.2.2. By Value (Forecast 2016E-2021F)

4.4. Global CKD Anemia Drugs Market
4.4.1. By Value (Historic 2011-15)
4.4.2. By Value (Forecast 2016E-2021F)

4.5. Global Sickle Cell Anemia Drugs Market
4.5.1. By Value (Historic 2011-15)
4.5.2. By Value ( Forecast 2016E-2021F)

4.6. Global Aplastic Anemia Drugs Market
4.6.1. By Value (Historic 2011-15)
4.6.2. By Value ( Forecast 2016E-2021F)

4.7. Anemia Drugs Pipeline Analysis
4.7.1. Sickle Cell Anemia
4.7.2. CKD Anemia
4.7.3. Aplastic Anemia
4.7.4. Iron Deficiency Anemia
4.7.5. Myelodysplastic syndrome Anemia

5. North America Anemia Drugs Market: An Analysis

5.1. North America Anemia Drugs Market
5.1.1.By Value (Historic 2011-15)
5.1.2.By Value (Forecast 2016E-2021F)

5.2. North America Anemia Drugs Market: Country Overview – US, Canada
6. Europe Anemia Drugs Market: An Analysis

6.1. Europe Anemia Drugs Market
6.1.1. By Value (Historic 2011-15)
6.1.2. By Value (Forecast 2016E-2021F)

6.2. Europe Anemia Drugs Market: Country Overview – UK, Germany

7. APAC Anemia Drugs Market: An Analysis

7.1. APAC Anemia Drugs Market
7.1.1.By Value (Historic 2011-15)
7.1.2.By Value (Forecast 2016E-2021F)

7.2. North America Anemia Drugs Market: Country Overview – India

8. Latin America Anemia Drugs Market: An Analysis

8.1. Latin America Anemia Drugs Market
8.1.1.By Value (Historic 2011-15)
8.1.2.By Value (Forecast 2016E-2021F)

8.2. Latin America Anemia Drugs Market: Country Overview – Brazil

9. MEA Anemia Drugs Market: An Analysis

9.1. MEA Anemia Drugs Market
9.1.1.By Value (Historic 2011-15)
9.1.2.By Value (Forecast 2016E-2021F)

9.2. MEA Anemia Drugs Market: Country Overview – South Africa

10. Market Dynamics
10.1. Trends
10.2. Drivers
10.3. Challenges

11. M&A and Licensing Route to the Anemia Drugs Treatment Market
12. SWOT Analysis

13. Porter Five Force Model

14. Company Profiling and Drug Market Potential

Sickle Cell Anaemia

14.1. Global Blood Therapeutics (GBT)
14.1.1. Company Overview
14.1.2. GBT-440 (Drug of Global Blood Therapeutics)
14.1.2.1 Market Potential

14.2. Bluebird bio
14.2.1. Company Overview
14.2.2. LentiGlobin BB305 (Drug of Bluebird bio)
14.2.2.1 Stage of development
14.2.2.2 Overview
14.2.2.3 Clinical Data
14.2.2.4 Market Potential

14.3. GlycoMimetics
14.3.1. Company Overview
14.3.2. Rivipansel (Drug of GlycoMimetics)
14.3.2.1 Stage of development
14.3.2.2 Overview
14.3.2.3 Clinical Data
14.3.2.4 Market Opportunity

14.4.Mast Therapeutics
14.4.1. Company Overview
14.4.2. Vepoloxamer (Drug of Mast Therapeutics)
14.4.2.1 Stage of development
14.4.2.2 Overview
14.4.2.3 Clinical Data
14.4.2.4 Market Potential

CKD Anemia

14.5. GlaxoSmithKline
14.5.1. Company Overview
14.5.2. Daprodustat (Drug of GlaxoSmithKline)
14.5.2.1 Stage of development
14.5.2.2 Overview
14.5.2.3 Clinical Data

14.6. Fibrogen
14.6.1. Company Overview
14.6.2. Roxadustat (Drug of Fibrogen)
14.6.2.1 Stage of development
14.6.2.2 Overview
14.6.2.3 Clinical Data

14.7. Akebia therapeutics
14.7.1. Company Overview
14.7.2. Vadadustat (Product of Akebia therapeutics)
14.7.2.1 Stage of development
14.7.2.2 Overview
14.7.2.3 Clinical Data

14.8. Bayer AG
14.8.1. Company Overview
14.8.2. Molidustat (Drug of Bayer)
14.8.2.1 Stage of development
14.8.2.2 Overview
14.8.2.3 Clinical Data

14.9. Eli Lilly
14.9.1. Company Overview
14.9.2. BMP-6 Mab (Drug of Eli Lilly)
14.9.2.1 Stage of development 
14.9.2.2 Overview
14.9.2.3 Clinical Data
14.9.3. Sotatercept (Drug of Eli Lilly)
14.9.3.1 Stage of development 
14.9.3.2 Overview
14.9.3.3 Clinical Data

Aplastic Anemia

14.10. Regen biopharma
14.10.1. Hemaxellerate (Product of Regen biopharma)
14.10.1.1 Overview
14.10.1.2 Stage of development 
14.10.2 BL-8040 (Drug of Bioline RX)
14.10.2.1 Overview
14.10.2.2 Stage of development 
14.10.2.3 Clinical Data
Myelodysplastic syndrome

14.11. Acceleron Pharma

14.12. Celgene Corporation
14.12.1. Luspatercept (Drug of Acceleron Pharma and Celgene Corporation)
14.12.1.1 Overview
14.12.1.2 Stage of development 
14.12.1.3 Clinical Data

14.13. Onconova Therapeutics
14.13.1 Luspatercept (Drug of Acceleron Pharma and Celgene Corporation)
14.13.1.1 Overview
14.13.1.2 Stage of development 
14.13.1.3 Clinical Data

Iron Deficiency Anemia

14.14. Pieris Pharmaceuticals
14.14.1. PRS-080 (Drug of Pieris Pharmaceuticals)
14.14.1.1 Overview
14.14.1.2 Stage of development 
14.14.1.3 Clinical Data
List of Figures

Figure 1: Global Anemia Drugs Market, 2011-2015 (USD Billion)
Figure 2: Global Anemia Drugs Market , 2016E-2021F (USD Billion)
Figure 3: Global Iron Deficiency Anemia Drugs Market, By Value, 2011-2015 (in USD Billion)
Figure 4: Global Iron Deficiency Anemia Drugs Market, By Value, 2016-2021F (in USD Billion)
Figure 5: Global CKD Anemia Drug Market, By Value, 2011-2015 (in USD Billion)
Figure 6: Global CKD Anemia Drug  Market, By Value, 2016-2021F (in USD Billion)
Figure 7: Global Sickle Cell Anemia Drug Market , By Value, 2011-2015 (in USD Million)
Figure 8: Global Sickle Cell Anemia Drug Market , By Value, 2016-2021F (in USD Million)
Figure 9: Global Aplastic Anemia Drugs Market, By Value, 2011-2015 (in USD Million)
Figure 10: Global Aplastic Anemia Drugs Market, By Value, 2016-2021F (in USD Million)
Figure 11: North America Anemia Drugs Market , 2011-2015 (USD Billion)
Figure 12: North America Anemia Drugs Market , 2016E- 2021F (USD Billion)
Figure 13: USA Anemia Drugs Market Size, By Value, 2011-2015 (in USD Billion)
Figure 14: USA Anemia Drugs Market Size, By Value, 2016-2021F (in USD Billion)
Figure 15: Population in USA with Health Insurance
Figure 16: Canada Anemia Drugs Market Size, By Value, 2011-2015 (in USD Million)
Figure 17: Canada Anemia Drugs Market Size, By Value, 2016-2021F (in USD Million)
Figure 18: Europe Anemia Drugs Market, 2011-2015 (USD Billion)
Figure 19: Europe Anemia Drugs Market, 2016E- 2021F (USD Billion)
Figure 20: UK Anemia Drugs Market Size, By Value, 2011-2015 (in USD Million)
Figure 21: UK Anemia Drugs Market Size, By Value, 2016-2021F (in USD Million)
Figure 22: Germany Anemia Drugs Market Size, By Value, 2011-2015 (in USD Million)
Figure 23: Germany Anemia Drugs Market Size, By Value, 2016-2021F (in USD Million)
Figure 24: APAC Anemia Drugs Market, 2011-2015 (USD Billion)
Figure 25: APAC Anemia Drugs Market, 2016E - 2021F (USD Billion)
Figure 26: India Anemia Drugs Market Size, By Value, 2011-2015 (in USD Million)
Figure 27: India Anemia Drugs Market Size, By Value, 2016-2021F (in USD Million)
Figure 28: Latin America Anemia Drugs Market, 2011-2015 (USD Million)
Figure 29: Latin America Drugs Treatment Market, 2016E- 2021F (USD Million)
Figure 30: Brazil Anemia Drugs Market Size, By Value, 2011-2015 (in USD Million)
Figure 31: Brazil Anemia Drugs Market Size, By Value, 2016-2021F (in USD Million)
Figure 32: MEA Anemia Drugs Market , 2011-2015 (USD Million)
Figure 33: MEA Anemia Drugs Market , 2016E- 2021F (USD Million)
Figure 34: South Africa Anemia Drugs Market Size, By Value, 2011-2015 (in USD Million)
Figure 35: South Africa Anemia Drugs Market Size, By Value, 2016-2021F (in USD Million)
Figure 36: Market Potential of GBT - 440
Figure 37: Testing of Lentiglobin
Figure 38: Market Potential of LentiGlobin BB305



List of Tables

Table 1:  Market Potential of GBT-440 on the Basis of Estimated Cases of Sickle cell Anemia
Table 2:  Market Potential of LentiGlobin BB305  on the Basis of Estimated Cases of Sickle cell Anemia

One can also purchase any particular sections from this report. Please send us an email to info@azothanalytics.com with your order details.
 
 
 
 
 Latest Market Research Reports